Literature DB >> 31708699

Low Incidence of Pump-Related Infections in Jarvik 2000 Ventricular Assist Device Recipients with a Subcostal Driveline Exit Site.

George V Letsou, Jatin Anand, Erinn Ogburn, Rohan M Shah, Anand V Ganapathy, William E Cohn, Gabriel Loor, O H Frazier.   

Abstract

Driveline infection has been a persistent problem with mechanical cardiac assist devices. The reported incidence of infection has been low in patients who receive a Jarvik 2000 continuous-flow left ventricular assist device when a skull-pedestal driveline exit site is used. We evaluated whether this is also true when a subcostal driveline exit site is used. We reviewed baseline demographic variables, postimplantation vital signs, laboratory values, and culture results in patients who underwent Jarvik 2000 implantation at our center from April 2000 through October 2009, including follow-up through June 2014. All patients had a subcostal driveline exit site. We defined device-related infection as a positive blood or wound culture associated with a medical or surgical device intervention. Event and time-to-event rates were calculated. Eighty-one patients received 89 Jarvik 2000 devices, all as bridges to transplantation. The median support duration was 69 days (interquartile range, 27-153 d; range, 2-2,249 d). Five superficial driveline infections and one incision-site infection occurred (0.002 events per patient-year of support). The median time from pump implantation to onset of driveline infection was 30 days; the incision-related infection occurred at 44 days. The Jarvik 2000 has a low incidence of infection when implanted with use of a subcostal driveline exit site. The incidence of pump infections is particularly low. Using a subcostal driveline exit site may be as effective in preventing infections as using a skull-pedestal driveline exit site. We detail our findings in this report.
© 2019 by the Texas Heart® Institute, Houston.

Entities:  

Keywords:  Disease-free survival; heart failure/therapy; heart-assist devices/adverse effects/statistics & numerical data; postoperative complications/microbiology; prosthesis design; prosthesis-related infections/etiology; retrospective studies; ventricular dysfunction, left/therapy

Mesh:

Year:  2019        PMID: 31708699      PMCID: PMC6827473          DOI: 10.14503/THIJ-15-5708

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN: 0730-2347


  16 in total

1.  Long-term use of a left ventricular assist device for end-stage heart failure.

Authors:  E A Rose; A C Gelijns; A J Moskowitz; D F Heitjan; L W Stevenson; W Dembitsky; J W Long; D D Ascheim; A R Tierney; R G Levitan; J T Watson; P Meier; N S Ronan; P A Shapiro; R M Lazar; L W Miller; L Gupta; O H Frazier; P Desvigne-Nickens; M C Oz; V L Poirier
Journal:  N Engl J Med       Date:  2001-11-15       Impact factor: 91.245

2.  Outcomes in advanced heart failure patients with left ventricular assist devices for destination therapy.

Authors:  Soon J Park; Carmelo A Milano; Antone J Tatooles; Joseph G Rogers; Robert M Adamson; D Eric Steidley; Gregory A Ewald; Kartik S Sundareswaran; David J Farrar; Mark S Slaughter
Journal:  Circ Heart Fail       Date:  2012-01-26       Impact factor: 8.790

Review 3.  Multicenter experience: prevention and management of left ventricular assist device infections.

Authors:  Raymond Chinn; Walter Dembitsky; Laura Eaton; Suzanne Chillcott; Marcia Stahovich; Brad Rasmusson; Francis Pagani
Journal:  ASAIO J       Date:  2005 Jul-Aug       Impact factor: 2.872

Review 4.  The Jarvik-2000 ventricular assist device implantation: how we do it.

Authors:  Fabio Zucchetta; Vincenzo Tarzia; Tomaso Bottio; Gino Gerosa
Journal:  Ann Cardiothorac Surg       Date:  2014-09

5.  Hemolysis: a harbinger of adverse outcome after left ventricular assist device implant.

Authors:  Jennifer A Cowger; Matthew A Romano; Palak Shah; Neha Shah; Vivek Mehta; Jonathan W Haft; Keith D Aaronson; Francis D Pagani
Journal:  J Heart Lung Transplant       Date:  2013-11-28       Impact factor: 10.247

6.  Pre-operative risk factors of bleeding and stroke during left ventricular assist device support: an analysis of more than 900 HeartMate II outpatients.

Authors:  Andrew J Boyle; Ulrich P Jorde; Benjamin Sun; Soon J Park; Carmelo A Milano; O Howard Frazier; Kartik S Sundareswaran; David J Farrar; Stuart D Russell
Journal:  J Am Coll Cardiol       Date:  2013-12-11       Impact factor: 24.094

7.  Advanced heart failure treated with continuous-flow left ventricular assist device.

Authors:  Mark S Slaughter; Joseph G Rogers; Carmelo A Milano; Stuart D Russell; John V Conte; David Feldman; Benjamin Sun; Antone J Tatooles; Reynolds M Delgado; James W Long; Thomas C Wozniak; Waqas Ghumman; David J Farrar; O Howard Frazier
Journal:  N Engl J Med       Date:  2009-11-17       Impact factor: 91.245

8.  Evolution and impact of drive-line infection in a large cohort of continuous-flow ventricular assist device recipients.

Authors:  Christine E Koval; Lucy Thuita; Nader Moazami; Eugene Blackstone
Journal:  J Heart Lung Transplant       Date:  2014-06-05       Impact factor: 10.247

9.  Late-onset driveline infections: the Achilles' heel of prolonged left ventricular assist device support.

Authors:  Andreas Zierer; Spencer J Melby; Rochus K Voeller; Tracey J Guthrie; Gregory A Ewald; Kim Shelton; Michael K Pasque; Marc R Moon; Ralph J Damiano; Nader Moazami
Journal:  Ann Thorac Surg       Date:  2007-08       Impact factor: 4.330

10.  Clinical manifestations and management of left ventricular assist device-associated infections.

Authors:  Juhsien Jodi C Nienaber; Shimon Kusne; Talha Riaz; Randall C Walker; Larry M Baddour; Alan J Wright; Soon J Park; Holenarasipur R Vikram; Michael R Keating; Francisco A Arabia; Brian D Lahr; M Rizwan Sohail
Journal:  Clin Infect Dis       Date:  2013-08-13       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.